Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literatureMeta-Analysis Published on 2023-02-012023-06-12 Journal: Journal of viral hepatitis [Category] B형 간염, [키워드] Acute-on-chronic liver failure Artificial liver support system Clinical studies Hepatitis B virus Meta-analysis [DOI] 10.1111/jvh.13767 [Article Type] Meta-Analysis
Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 ResultsCoronary Heart Disease Published on 2023-01-232024-09-05 Journal: Journal of the American Heart Association [Category] update2024, [키워드] acute coronary syndromes Atherosclerosis cardiovascular disease Clinical studies coronary CTA diabetes Diabetes, Type 2 Inflammation LOX‐1 [DOI] 10.1161/JAHA.122.027540 PMC 바로가기 [Article Type] Coronary Heart Disease
A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Care characterized circulation Clinical studies collected coronavirus defined Delta demonstrated diagnostic diagnostic capability effort functional health system health systems identify increasingly Infection prevention Iota Laboratory MALDI-TOF mass molecular MOST multiplex New York City omicron Panel Patient Patient care polymorphism Population public health measures public health systems RNA robust RT-PCR SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 variant seeking sensitivity specificity specimen Spectrometry Surveillance target tested Transmissibility USA utility vaccination variant variant call variant panel. virus WGS while whole-genome sequencing [DOI] 10.1128/spectrum.01736-22 PMC 바로가기
Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virusSARS-CoV-2, MERS-CoV, 에볼라, 지카, HIV-1 및 인플루엔자 A 바이러스에 특히 중점을 두고 중요한 신흥 바이러스 병원체에 대응하는 강력한 생물 치료제로서의 형질전환 소 유래 광범위 중화 항체Review Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adjuvant adjuvants Alpha animals antibody antibody-based therapies Antiviral approach approved assist Beta Biotherapeutics blocked bovine bovine-derived biotherapeutics Clinical studies colostrum convalescent coronavirus creating Delta disease Donor E484K Ebola effective Efficiency emerging viruses Epsilon Gamma highlight HIV-1 Human Human immunodeficiency virus human immunodeficiency virus type 1 human infection human infections hyperimmunization immune immunoreactivity Immunotherapy Influenza influenza A influenza A virus Iota K417N L452R Lambda MERS MERS-CoV Middle East Middle East respiratory syndrome Coronavirus mutations N501Y neutralization neutralized Neutralizing Neutralizing activity neutralizing antibody omicron Omicron variants outbreak P681R Pandemics platform polyclonal antibodies polyclonal antibody produced Protective respiratory respiratory syndrome coronavirus robust Safe SARS-CoV-2 serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown T478K therapeutic option transchromosomic bovines. Vaccine variant variants variants of concern variants of interest Viral viral infection viral infections viral pathogen VOCs VOIs Zika [DOI] 10.1002/jmv.27907 PMC 바로가기 [Article Type] Review
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2Article Published on 2022-09-162022-11-15 Journal: Frontiers in Immunology [Category] SARS, 치료제, [키워드] adaptive Adaptive immune response Adaptive immunity addition animal model anti-SARS-CoV-2 Antiviral Clinical studies clinical symptom COVID-19 cross-immune response drugs humans immune immune memory immune response Immunity in-depth analysis Infection limitation mechanism mechanisms persistence PROTECT Protective provide Research SARS-CoV-2 the SARS-CoV-2 thresholds tissue-resident immune response. Vaccine [DOI] 10.3389/fimmu.2022.993754 PMC 바로가기
mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cellsArticle Published on 2022-09-072022-11-16 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] antibody antigen-presenting cells appear B cell biodistribution Cancer Cancer vaccine CD8 T cell changes in Clinical studies design-of-experiments methodology effective extrahepatic delivery histopathological Immune cell immune cell populations Immunity immunization Immunotherapy induce interferon liver LNP mechanism methodology mRNA mRNA expression non-human primate phagocyte provide response responses SARS-CoV-2 spleen stimulatory systemic T cell T cell response the vaccine Type vaccination Vaccine [DOI] 10.1016/j.ymthe.2022.07.007 PMC 바로가기
In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19통합 전사체 프로파일링 접근법을 사용하여 SARS-CoV-2에 대한 인실리코 약물 용도 변경: COVID-19에 대한 잠재적 약물 후보로서 히드로코르티손 및 벤즈히드로코돈Article Published on 2022-09-012022-09-11 Journal: Infection, genetics and evolution : journal of mol [Category] COVID19(2023년), SARS, 변종, 신약개발, 유전자 메커니즘, 치료제, [키워드] ADAR alveolar cell Analysis Anti-viral antiviral immune response Benzhydrocodone binding affinity CASP1 cellular response Cellular responses Clinical studies clinical study complementary COVID-19 COVID-19 pathogenesis determine drug drug candidate Drug repurposing dysregulated enrichment enrichment analysis evaluated FDA-approved drug FOS hallmark HBEGF Host Hydrocortisone ICAM1 identify IFI35 immune system in silico in silico approaches in viral in vitro in vivo experiment infected with SARS-CoV-2 Infectious disease involved IRF2 JUN management MMP9 molecular molecular docking Pathogenesis pathway Pathways promise Protein protein-protein interaction Proteins Repurposed drug Repurposed drugs SARS-CoV-2 SARS-COV-2 infection Signal transduction STAT3 subject suggested transcriptomic transcriptomic profile transcriptomics up-regulated USP18 viral infectious disease [DOI] 10.1016/j.meegid.2022.105318 PMC 바로가기 [Article Type] Article
Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus MonkeysArticle Published on 2022-09-012022-11-15 Journal: Pharmaceutical research [Category] COVID19(2023년), SARS, 진단, [키워드] aerosol alternative route animal model antibodies antibody antibody concentration approach caused Clinical studies Concentration demonstrated Diseases dose epithelial lining feasibility humanized monoclonal antibody inhalation intravenous Intravenous injection lung mice Mild Moderate COVID-19 Monkey nebulized Neutralizing neutralizing antibody pharmacokinetics PRNT reached remained respiratory tract safety profile SARS-CoV-2 SARS-COV-2 infection serum shown single dose Transport treating COVID-19 was used [DOI] 10.1007/s11095-022-03340-9 PMC 바로가기
Pseudoscience and fraudulent products for COVID-19 managementArticle Published on 2022-09-012022-11-16 Journal: Environmental science and pollution research inter [Category] COVID19(2023년), SARS, 변종, [키워드] agency claimed Clinical data Clinical studies Complete country COVID-19 COVID-19 pandemic defined Depression effective Emergency use FDA Fraudulent product Health healthcare worker management Medicine mutated myth pandemic patients protective immunity Pseudoscience Randomized regulatory agency SARS-CoV-2 strain the disease Treatment Vaccine variant viral variant [DOI] 10.1007/s11356-022-21967-4 PMC 바로가기
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devicesCOVID-19에 대한 흡입 요법: 약물, 제형 및 장치에 대한 고려 사항Review Published on 2022-08-252022-09-11 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Administered administration anti-SARS-CoV-2 antiviral drug antiviral drugs Antiviral treatment approach Clinical studies Combinational Concentration coronavirus COVID-19 COVID-19 pandemic Device disease dose drug drug combination drug susceptibility drugs effective effective vaccine Efficacy etiological agent include Infection inhalation Inhaled intravenous key consideration limitations lower dose lung majority mono potency preclinical studies reduce reduced responsible SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown Side effects tested therapy Treatment treatment for COVID-19 [DOI] 10.1016/j.ijpharm.2022.122042 PMC 바로가기 [Article Type] Review